ASH 2018 | Venetoclax-resistance conferring mutation in CLL identified
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Despite the high response rates seen with venetoclax treatment in patients with heavily pre-treated chronic lymphocytic leukemia (CLL), disease in most patients will eventually progress. Piers Blombery, MBBS, FRCPA, FRACP, of the University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a new recurrent BCL2 mutation (Gly101Val) appearing in a cohort of CLL patients who progress following venetoclax treatment. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Blomery reveals how this provides a new look into the pathobiology of venetoclax resistance, offering a potential biomarker to predict clinical relapse.
Get great new content delivered to your inboxSign up